A detailed history of Bender Robert & Associates transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bender Robert & Associates holds 24,307 shares of BMY stock, worth $1.31 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
24,307
Previous 27,442 11.42%
Holding current value
$1.31 Million
Previous $1.49 Million 32.19%
% of portfolio
0.22%
Previous 0.35%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

SELL
$47.98 - $54.4 $11,995 - $13,600
-250 Reduced 0.9%
27,442 $1.49 Million
Q4 2023

Jan 31, 2024

SELL
$48.48 - $57.85 $242 - $289
-5 Reduced 0.02%
27,692 $1.42 Million
Q3 2023

Oct 13, 2023

SELL
$57.89 - $64.73 $34,734 - $38,838
-600 Reduced 2.12%
27,697 $1.61 Million
Q2 2023

Jul 13, 2023

BUY
$63.71 - $70.74 $26,121 - $29,003
410 Added 1.47%
28,297 $1.81 Million
Q1 2023

Apr 20, 2023

SELL
$65.71 - $74.53 $3,942 - $4,471
-60 Reduced 0.21%
27,887 $1.93 Million
Q3 2022

Oct 26, 2022

BUY
$0.13 - $76.84 $375 - $221,683
2,885 Added 11.51%
27,947 $1.99 Million
Q2 2022

Jul 19, 2022

SELL
$72.62 - $79.98 $21,786 - $23,994
-300 Reduced 1.18%
25,062 $1.93 Million
Q1 2022

Apr 14, 2022

BUY
$61.48 - $73.72 $610,926 - $732,555
9,937 Added 64.42%
25,362 $1.85 Million
Q3 2021

Nov 03, 2021

BUY
$59.17 - $69.31 $3,905 - $4,574
66 Added 0.43%
15,425 $913,000
Q2 2021

Jul 16, 2021

BUY
$61.91 - $67.42 $97,817 - $106,523
1,580 Added 11.47%
15,359 $1.03 Million
Q1 2021

Apr 28, 2021

BUY
$59.34 - $66.74 $50,498 - $56,795
851 Added 6.58%
13,779 $870,000
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $57 - $65
1 Added 0.01%
12,928 $802,000
Q3 2020

Oct 29, 2020

BUY
$57.43 - $63.64 $11,543 - $12,791
201 Added 1.58%
12,927 $779,000
Q2 2020

Jul 31, 2020

BUY
$54.82 - $64.09 $140,339 - $164,070
2,560 Added 25.18%
12,726 $748,000
Q1 2020

Apr 21, 2020

SELL
$46.4 - $67.43 $1,809 - $2,629
-39 Reduced 0.38%
10,166 $567,000
Q4 2019

Jan 31, 2020

SELL
$49.21 - $64.19 $7,873 - $10,270
-160 Reduced 1.54%
10,205 $655,000
Q3 2019

Oct 15, 2019

SELL
$42.77 - $50.71 $19,973 - $23,681
-467 Reduced 4.31%
10,365 $526,000
Q2 2019

Jul 30, 2019

SELL
$44.62 - $49.34 $37,436 - $41,396
-839 Reduced 7.19%
10,832 $491,000
Q1 2019

Apr 30, 2019

SELL
$45.12 - $53.8 $4,512 - $5,380
-100 Reduced 0.85%
11,671 $557,000
Q4 2018

Jan 24, 2019

SELL
$48.76 - $63.23 $19,942 - $25,861
-409 Reduced 3.36%
11,771 $612,000
Q2 2018

Jul 27, 2018

SELL
$50.53 - $62.98 $19,656 - $24,499
-389 Reduced 3.09%
12,180 $674,000
Q1 2018

Apr 27, 2018

SELL
$59.92 - $68.98 $6,591 - $7,587
-110 Reduced 0.87%
12,569 $795,000
Q4 2017

Jan 19, 2018

SELL
$59.94 - $65.35 $19,420 - $21,173
-324 Reduced 2.49%
12,679 $777,000
Q3 2017

Oct 23, 2017

BUY
$55.23 - $63.74 $718,155 - $828,811
13,003
13,003 $829,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bender Robert & Associates Portfolio

Follow Bender Robert & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Bender Robert & Associates with notifications on news.